Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anitha Police

Internal Medicine Jacksonville, FL Medical Doctor

NPI 1821127903 CMS profile 38014

14534 Old Saint Augustine Rd Ste 3120, Jacksonville, FL 32258

Open in the dashboard

General payments

$6,722

396 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anitha Police of Jacksonville, FL is reported in the CMS Open Payments database as having received $6,722 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,016 54
2024 General $1,103 60
2023 General $1,206 68
2022 General $710 44
2021 General $1,057 62
2020 General $837 54
2019 General $793 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anitha Police
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anitha Police were reported at $1,016. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anitha Police Internal Medicine median Middle half National median
2019 $793 $159 $48–$570 $163
2020 $837 $119 $33–$402 $114
2021 $1,057 $135 $37–$521 $132
2022 $710 $141 $42–$496 $149
2023 $1,206 $149 $45–$519 $160
2024 $1,103 $154 $47–$537 $164
2025 $1,016 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,424 88 payments
  2. Lilly USA, LLC $759 48 payments
  3. GlaxoSmithKline, LLC. $419 23 payments
  4. Abbott Laboratories $417 20 payments
  5. AbbVie, Inc. $379 28 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $372 22 payments
  7. Amgen Inc. $355 23 payments
  8. AstraZeneca Pharmaceuticals LP $328 20 payments
  9. Biohaven Pharmaceuticals, Inc. $237 9 payments
  10. Astellas Pharma US Inc $224 11 payments
  11. Other $1,808 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,722 396 payments
Products named General payments · program years 2019–2025
  1. Ozempic $688 41 payments
  2. RYBELSUS $504 30 payments
  3. Wegovy $410 24 payments
  4. MOUNJARO $380 25 payments
  5. NURTEC ODT $334 13 payments
  6. FreeStyle Libre 3 $334 15 payments
  7. JARDIANCE $289 17 payments
  8. Otezla $275 18 payments
  9. Repatha $267 17 payments
  10. TRELEGY ELLIPTA $245 14 payments
  11. Other $5,280 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

6,506

Median for Internal Medicine: 777

Drug cost

$537,145

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 89 $112,446
Eliquis Apixaban Brand 61 $65,190
Mounjaro Tirzepatide Brand 33 $54,154
Jardiance Empagliflozin Brand 33 $40,693
Trulicity Dulaglutide Brand 34 $35,849
Glyxambi Empagliflozin/Linagliptin Brand 29 $34,012
Januvia Sitagliptin Phosphate Brand 21 $31,051
Tradjenta Linagliptin Brand 22 $28,145
Myrbetriq Mirabegron Brand 18 $19,434
Breo Ellipta Fluticasone/Vilanterol Brand 24 $13,523

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$121,277

Of which drugs: $2,444

Medicare patients

358

Average age 74

Services billed

2,471

276 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 18%
Osteoporosis 18%
Atrial fibrillation 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 21 21 $1,718
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 13 350 $80
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 19 77 $71
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 108 $54
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 56 $20
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg J7614 Office 21 64 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $109
$109 33 —
JARDIANCE
  • Lilly USA, LLC $54
  • Boehringer Ingelheim Pharmaceuticals, Inc. $35
$89 33 —
Wegovy
  • Novo Nordisk Inc $66
$66 — —
RYBELSUS
  • Novo Nordisk Inc $63
$63 — —
Ozempic
  • Novo Nordisk Inc $63
$63 89 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record